NCT06105671

U-LABA/ICS Effects on Exercise Performance, Formoterol

Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Morten Hostrup, PhD · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current standard procedures.

Conditions

• Exercise Performance

Interventions

Type	Name	Description
DRUG	Symbicort	Participants are administered 54 μg Formoterol and 1920 μg Budesonide
DRUG	Formoterol	Participants are administered 54 μg Formoterol from an inhaler device
DRUG	Formoterol	Participants are administered 120 μg Formoterol in a capsule, which is taken orally
DRUG	Placebo	Participants are administered placebo
DRUG	Mannitol	Participants are administered 600 mg Bronchitol

Timeline

• Start date: 2024-01-05
• Primary completion: 2024-07-04
• Completion: 2024-07-04
• First posted: 2023-10-30
• Last updated: 2024-08-13

Locations

1 site across 1 country: Denmark